Skip to content

Rationale and design of Diabetes Management with curcumin and saffron (DMCS): a randomised, three blind -blind, placebo-controlled study

Investigating the effects of curcumin and saffron on fertility, sugar, lipid and anthropometric indicators in women with diabetes mellitus of reproductive age

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20160809029281N4
Enrollment
120
Registered
2024-05-09
Start date
2024-06-10
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus. Diabetes mellitus(E10-E14)

Interventions

Intervention 1: Curcumin group of two curcumin capsules daily with a dose of 500 mg. Intervention 2: Daily saffron group of one saffron capsules with a dose of 15 mg and one placebo capsule. Intervent

Sponsors

Yazd University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 54 Years

Inclusion criteria

Inclusion criteria: Married Women of reproductive age with diabetes mellitus Treated for at least one year Not being dependent on insulin Being between the ages of 18-45 Having a body mass index between 18.5 and 30. Absence of menorrhagia on the basis of the PBLAC chart

Exclusion criteria

Exclusion criteria: Unwillingness to participate in the study, under insulin treatment

Design outcomes

Primary

MeasureTime frame
Sugar indices (FBS, HA1c, 2HPP) and fat indices (LDL, HDL, TG), fertility index including stress, anxiety and depression, quality of sexual life, Anthropometric indexsexual performance and marital satisfaction. Timepoint: at baseline and one week Completion of the intervention. Method of measurement: will be measured using Delta DP diagnostic kits(31)?It is measured using Delta DP diagnostic kits. Using DASS, FSFI, SQFL, KMS questionnaires,Standardized weights and meters.

Secondary

MeasureTime frame
Clinical symptoms of diabetes, drug side effects and drug adherence. Timepoint: At first, every two weeks after the start of the intervention and one week after the end of the intervention. Method of measurement: Measurement of medication adherence with the MMAS-8 medication adherence questionnaire, examination of medication side effects and clinical symptoms with a researcher-made questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactfateme moshirenia

Yazd University of Medical Sciences

f.moshirenia@gmail.com+98 35 3272 2393

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026